ART26.12

FABP Inhibitor Program for CIPN, Psoriasis,
Other Painful Neuropathies & Various Cancers

ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with initial clinical development planned for chemotherapy-induced peripheral neuropathy (CIPN).

Fatty Acid Binding Proteins (FABPs) are a family of intracellular transport proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies.  Beyond ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.

Learn more about ART26.12

Scientific and Clinical Validation

  • Phase 1 clinical data from completed SAD and food effect demonstrated:
    • Excellent Safety Profile: All adverse events (AEs) were mild, transient, and self-resolving and believed by medical staff not related to study drug
    • Predictable Pharmacokinetics: Plasma analysis confirmed dose-dependent linear absorption
    • Therapeutic Window: A wide safety margin was observed between estimated therapeutic plasma concentrations and the highest exposure levels achieved.
    • Potential for dosing fed or fasted
  • FABP5 inhibition may have therapeutic value in Chemotherapy-Induced Peripheral Neuropathy (CIPN), other painful neuropathies, and dermatology
  • FABP5 is a validated target in breast, prostate and cervical cancers, and is implicated in many other cancer types

Formulation and Intellectual Property

  • Three patents issued
  • 14 patent applications pending, with two additional planned

Opportunity

  • Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  • Cancer (including breast and prostate cancers)
  • Generalized anxiety
  • Dermatology (Psoriasis)